Cited by 77Thyroid Disorders and TreatmentsDrug Solubulity and Delivery SystemsThyroid and Parathyroid Surgery

The Acute Effect of Calcium Carbonate on the Intestinal Absorption of Levothyroxine

Singh, Nalini, Weisler, Shawna L., Hershman, Jerome M.·2001·Thyroid

Abstract

To determine the acute effect of calcium, we measured levothyroxine absorption after ingestion of thyroxine (T4) with and without simultaneous ingestion of calcium (as calcium carbonate) in seven volunteers without thyroid disease. Serum total T4, total triiodothyronine (T3), free T4, and thyrotropin (TSH) levels were measured after ingestion of 1,000 microg of levothyroxine on two separate visits at 4-week intervals: (1) levothyroxine alone and (2) levothyroxine together with 2.0 g of calcium as calcium carbonate. The amount of absorbed levothyroxine was calculated as the incremental rise in serum T4 level during the first 6 hours multiplied by the volume of distribution for the hormone. When 1,000 microg of levothyroxine alone was given to subjects, the maximum average total T4 absorption was 837 microg (83.7% of the dose ingested) at 120 minutes. When levothyroxine was coadministered with 2.0 g of calcium (as calcium carbonate), the maximum average T4 absorption decreased to 579 microg (57.9% of the dose ingested) at 240 minutes. The total levothyroxine absorption over 6 hours was significantly greater with thyroxine than that with thyroxine and calcium (p = 0.02). The administration of calcium and levothyroxine in these subjects was associated with a significant reduction in the peak increment in serum total T4 (p = 0.02) and free T4 levels (p = 0.03), as well as a significant reduction in the overall increment in serum total T4 (p = 0.003), free T4 (p = 0.002), and total T3 levels (p = 0.01) over four time points (120 minutes, 240 minutes, 360 minutes, 1,440 minutes). In summary, this pharmacokinetic study in seven volunteers indicates that calcium carbonate acutely reduces T4 absorption.

Integrity signals

Registry

Crossref · 10.1089/105072501753211046

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The list of medications that can alter the absorption of LT4 is extensive and includes calcium carbonate, PPIs, bile acid sequestrants (cholestyramine and colesevelam), phosphate binders, ferrous sulfate, aluminum-containing antacids, and sucralfate.

    “The list of medications that can alter the absorption of LT4 is extensive and includes calcium carbonate (132-134), PPIs (135), bile acid sequestrants (cholestyramine and colesevelam) (136,137), phosphate binders (138,139), ferrous sulfate (140,141), aluminum-containing antacids (142,143), and sucralfate (144,145).”
  • A subsequent absorption study showed that both Cmax and AUC were reduced when calcium carbonate and LT4 were co-administered (133).

    “A subsequent absorption study showed that both the Cmax and AUC were reduced when calcium carbonate and LT4 were co-administered (133).”
  • Calcium carbonate adsorbed T4 dose-dependently at pH 2 but not pH 7.4, thus explaining L-T4 malabsorption, and reduced T4 pharmacokinetics.

    “Calcium carbonate adsorbed T4 dose-dependently at pH 2 but not pH 7.4, thus explaining L-T4 malabsorption (41), and reduced T4 pharmacokinetics (42).”

    From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [42]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Singh, N., Weisler, S. L., & Hershman, J. M.
Affiliations
VA Greater Los Angeles Healthcare System (US)
Venue
Thyroid
Published
2001-10
Volume
11
Issue
10
Pages
967-971
ISSN
  • 1050-7256 (ISSN-L)
  • 1557-9077
OpenAlex
W2168410270
Cited by
77
References
22
Citations by year
2026: 3 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 5 · 2013: 3 · 2012: 1
FWCI
0.92
Type
journal article
Language
en
Open access
closed
Locations
  • Thyroid (publishedVersion)
  • PubMed (publishedVersion)
Funders
Abbott Laboratories
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
Keywords
levothyroxine, calcium carbonate, intestinal absorption, drug-drug interactions, thyroid hormone absorption, serum thyroxine, triiodothyronine, thyroid-stimulating hormone, free thyroxine
MeSH terms
Adult, Calcium Carbonate, Female, Humans, Intestinal Absorption, Male, Thyrotropin, Thyroxine, Triiodothyronine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review